Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARREST-BP trial of nomacopan plus oral corticosteroids in bullous pemphigoid
NL-OMON51799Phase 3Withdrawn
- Sponsor
- Akari Therapeutics
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nomacopan in Bullous Pemphigoid (BP) (4 arms), sponsored by Akari Therapeutics. Planned start Nov 2021; status: withdrawn.
02
Drugs
nomacopan
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NL-OMON51799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51799.